Evolva appoints Norbert Bender as Chief Medical Officer
Evolva Holding SA (SIX: EVE) announced that it has appointed Norbert Bender, M.D, Ph.D., an experienced drug development professional, as its Chief Medical Officer (CMO) with immediate effect.
- (1888PressRelease) May 03, 2011 - Norbert Bender is an M.D. from the University of Frankfurt, Germany and has a Ph.D. in Biochemistry and Pharmacy from the same institution. He practiced for 10 years as a medical doctor in internal medicine at the Frankfurt University Hospital. He subsequently worked for more than 20 years in various senior functions in pharmaceutical (Hoechst, Knoll) and biotech companies (Cardion, Trigen, ViroLogik), in both Europe and North America.
Dr. Bender has particular expertise in the cardiovascular space and has been involved in the successful development of Ramipril and its fixed combinations, Reviparine, Sibutramine and Adalimumab. He will take the CMO post that has been vacant since the departure of Jessica Mann in 2010 and will be a member of the Group Management Team. He has been working as a medical consultant to Evolva since October 2010.
Neil Goldsmith, Managing Director and CEO of Evolva commented, “I welcome Norbert to our management team and look forward to his contribution to the progress of our programmes. Norbert has extensive experience both as a drug developer and as a practicing doctor. This will be of great value as our compounds progress along their development paths.”
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam